The popularity of Sildenafil initially drove a boom for pharma, but recent shifts present a uncertain outlook for those considering a stake. Off-patent alternatives are eroding revenue, and ongoing patent challenges https://kaitlyndimq847912.amoblog.com/the-blue-pill-and-pharma-a-risky-bet-63243820